|
US7605238B2
(en)
*
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
ATE354655T1
(de)
*
|
1999-08-24 |
2007-03-15 |
Medarex Inc |
Humane antikörper gegen ctla-4 und deren verwendungen
|
|
AR027404A1
(es)
|
2000-02-10 |
2003-03-26 |
Abbott Gmbh & Co Kg |
Anticuerpos que ligan la interleucina-18 humana y metodos de preparacion y uso.
|
|
AU2002231736A1
(en)
|
2000-12-22 |
2002-07-08 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
|
TNSN01177A1
(fr)
|
2001-01-05 |
2005-11-10 |
Pfizer |
Des anticorps pour le recepteur i de facteur de croissance insuline-like.
|
|
GEP20074091B
(en)
|
2001-04-26 |
2007-04-25 |
Biogen Idec Inc |
Cripto blocking antibodies and uses thereof
|
|
CA2447114A1
(en)
|
2001-05-16 |
2002-11-21 |
Abgenix, Inc. |
Human antipneumococcal antibodies from non-human animals
|
|
IL149701A0
(en)
*
|
2001-05-23 |
2002-11-10 |
Pfizer Prod Inc |
Use of anti-ctla-4 antibodies
|
|
KR101038585B1
(ko)
*
|
2001-06-26 |
2011-06-03 |
암젠 인코포레이티드 |
Ｏｐｇｌ 에 결합하는 항체, 이의 조성물 및 이의 제조방법
|
|
AU2006228095B2
(en)
*
|
2001-10-11 |
2010-11-04 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
MXPA04009418A
(es)
|
2002-03-29 |
2005-06-08 |
Schering Corp |
Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos.
|
|
MXPA04010013A
(es)
|
2002-04-12 |
2004-12-13 |
Medarex Inc |
Metodos de tratamiento utilizando anticuerpos al antigeno-4 asociado con el linfocito t citotoxico.
|
|
JP2006500931A
(ja)
*
|
2002-09-30 |
2006-01-12 |
ファイザー・プロダクツ・インク |
高レベルのヒト配列抗体を産生するハイブリドーマ
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
US7465446B2
(en)
|
2003-05-30 |
2008-12-16 |
Medarex, Inc. |
Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
|
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
|
JP2007528721A
(ja)
|
2003-08-14 |
2007-10-18 |
ダイアックス コーポレイション |
エンドセリアーゼ−２リガンド
|
|
AR045563A1
(es)
*
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
|
CA2552523C
(en)
|
2004-01-09 |
2019-11-26 |
Pfizer Inc. |
Monoclonal antibodies to mucosal addressin cell adhesion molecule(madcam)
|
|
WO2005092380A2
(en)
*
|
2004-03-26 |
2005-10-06 |
Pfizer Products Inc |
Uses of anti-ctla-4 antibodies
|
|
US7494779B2
(en)
|
2004-06-14 |
2009-02-24 |
Li-Te Chin |
Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
|
|
EP2287195B1
(en)
|
2004-07-01 |
2019-05-15 |
Novo Nordisk A/S |
Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
|
|
AU2005264063B2
(en)
|
2004-07-16 |
2009-09-10 |
Pfizer Products Inc. |
Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
|
|
WO2006056464A2
(en)
*
|
2004-11-26 |
2006-06-01 |
Pieris Ag |
Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
|
|
ES2569409T3
(es)
*
|
2005-03-08 |
2016-05-10 |
Pfizer Products Inc. |
Composiciones de anticuerpo anti-CTLA-4
|
|
AU2014240252B2
(en)
*
|
2005-03-08 |
2016-10-06 |
Pfizer Products Inc |
Anti-CTLA-4 Antibody Compositions
|
|
AU2012200203B2
(en)
*
|
2005-03-08 |
2014-07-03 |
Pfizer Products Inc. |
Anti-CTLA-4 Antibody Compositions
|
|
JP2006265155A
(ja)
*
|
2005-03-23 |
2006-10-05 |
Link Genomics Kk |
癌の免疫療法
|
|
AU2006227879A1
(en)
*
|
2005-03-23 |
2006-09-28 |
Pfizer Products Inc. |
Therapy of prostate cancer with CTLA4 antibodies and hormonal therapy
|
|
US7812135B2
(en)
|
2005-03-25 |
2010-10-12 |
Tolerrx, Inc. |
GITR-binding antibodies
|
|
DOP2006000093A
(es)
|
2005-04-25 |
2007-01-31 |
Pfizer |
Anticuerpos contra miostatina
|
|
EP2444420A1
(en)
|
2005-04-26 |
2012-04-25 |
Pfizer Inc. |
P-Cadherin antibodies
|
|
US20090041783A1
(en)
|
2005-04-28 |
2009-02-12 |
Mochida Pharmaceutical Co., Ltd. |
Anti-platelet membrane glycoprotein vi monoclonal antibody
|
|
JP5224707B2
(ja)
*
|
2005-04-28 |
2013-07-03 |
持田製薬株式会社 |
抗血小板膜糖蛋白質ｖｉモノクローナル抗体
|
|
WO2006121168A1
(en)
|
2005-05-09 |
2006-11-16 |
Ono Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
JP5788632B2
(ja)
|
2005-06-08 |
2015-10-07 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
プログラム細胞死１（ｐｄ−１）経路を阻害することによる持続感染および癌の処置のための方法および組成物
|
|
CN101268101A
(zh)
*
|
2005-07-07 |
2008-09-17 |
科利制药集团公司 |
用于癌症治疗的抗-CTLA-4抗体和含有CpG基序的合成寡脱氧核苷酸联合治疗
|
|
CN100443503C
(zh)
*
|
2005-07-18 |
2008-12-17 |
四川大学华西医院 |
人源化ctla-4单链抗体与人穿孔素通道形成肽p34的重组免疫毒素
|
|
EP2500355A3
(en)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
NZ612578A
(en)
|
2005-08-19 |
2014-11-28 |
Abbvie Inc |
Dual variable domain immunoglobin and uses thereof
|
|
EP2960253B1
(en)
|
2005-09-07 |
2018-06-06 |
Amgen Fremont Inc. |
Human monoclonal antibodies to activin receptor-like kinase-1
|
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
|
US8906864B2
(en)
|
2005-09-30 |
2014-12-09 |
AbbVie Deutschland GmbH & Co. KG |
Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
|
|
JP2009514977A
(ja)
|
2005-11-08 |
2009-04-09 |
メダレックス インコーポレーティッド |
免疫刺激性治療用抗体による治療に付随した腸炎に対するＴＮＦ−α遮断剤処置法
|
|
CA2631195C
(en)
|
2005-11-30 |
2016-04-05 |
Abbott Laboratories |
Monoclonal antibodies against amyloid beta protein and uses thereof
|
|
WO2007062852A2
(en)
|
2005-11-30 |
2007-06-07 |
Abbott Laboratories |
ANTI-Aβ GLOBULOMER ANTIBODIES, ANTIGEN-BINDING MOIETIES THEREOF, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, METHODS OF PRODUCING SAID ANTIBODIES, COMPOSITIONS COMPRISING SAID ANTIBODIES, USES OF SAID ANTIBODIES AND METHODS OF USING SAID ANTIBODIES
|
|
EP1954311A4
(en)
|
2005-12-07 |
2009-12-23 |
Medarex Inc |
CTLA-4 ANTIBODY DOSAGE ESCALATION THERAPY
|
|
US8216996B2
(en)
|
2006-03-03 |
2012-07-10 |
Ono Pharmaceutical Co., Ltd. |
Multimer of extracellular domain of cell surface functional molecule
|
|
JP6092497B2
(ja)
|
2006-03-30 |
2017-03-08 |
ユニバーシティー オブ カリフォルニア |
抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
|
|
US7919079B2
(en)
*
|
2006-03-31 |
2011-04-05 |
Biosante Pharmaceuticals, Inc. |
Cancer immunotherapy compositions and methods of use
|
|
CN101578297A
(zh)
|
2006-04-07 |
2009-11-11 |
美国政府健康及人类服务部 |
治疗肿瘤疾病的抗体组合物和方法
|
|
MX2009001291A
(es)
|
2006-08-04 |
2009-03-10 |
Astrazeneca Ab |
Anticuerpos para erbb2.
|
|
KR101625961B1
(ko)
|
2006-09-08 |
2016-05-31 |
애브비 바하마스 리미티드 |
인터루킨-13 결합 단백질
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
US8895004B2
(en)
|
2007-02-27 |
2014-11-25 |
AbbVie Deutschland GmbH & Co. KG |
Method for the treatment of amyloidoses
|
|
EP2134855A4
(en)
|
2007-03-12 |
2011-01-05 |
Dana Farber Cancer Inst Inc |
USES OF FANCI AND FANCI MODULATING AGENTS IN PROGNOSIS, DIAGNOSIS AND CANCER THERAPY
|
|
WO2008123999A2
(en)
|
2007-04-02 |
2008-10-16 |
Amgen Fremont Inc. |
Anti-ige antibodies
|
|
DK2175884T3
(en)
|
2007-07-12 |
2016-09-26 |
Gitr Inc |
Combination USING GITR BINDING MOLECULES
|
|
WO2009045370A2
(en)
|
2007-09-28 |
2009-04-09 |
Intrexon Corporation |
Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
|
|
EP2612868B1
(en)
|
2007-11-01 |
2018-08-15 |
Astellas Pharma Inc. |
Immunosuppressive polypeptides and nucleic acids
|
|
US7960515B2
(en)
|
2007-12-14 |
2011-06-14 |
Bristol-Myers Squibb Company |
Binding molecules to the human OX40 receptor
|
|
KR20100100949A
(ko)
|
2008-01-08 |
2010-09-15 |
브리스톨-마이어스 스큅 컴퍼니 |
증식성 질환의 치료를 위한 튜불린 조정제와 항-ｃｔｌａ４ 항체의 조합물
|
|
WO2009100140A1
(en)
*
|
2008-02-04 |
2009-08-13 |
Medarex, Inc. |
Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
|
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
EP2282769A4
(en)
|
2008-04-29 |
2012-04-25 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
|
RU2518351C2
(ru)
|
2008-05-09 |
2014-06-10 |
Эббви Дойчланд Гмбх Унд Ко.Кг, |
Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применения
|
|
WO2009149189A2
(en)
|
2008-06-03 |
2009-12-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
|
EP2297208A4
(en)
|
2008-06-03 |
2012-07-11 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
|
MX2010014574A
(es)
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
|
BRPI0915825A2
(pt)
|
2008-07-08 |
2015-11-03 |
Abbott Lab |
proteínas de ligação à prostaglandina e2 usos das mesmas
|
|
US8119129B2
(en)
|
2008-08-01 |
2012-02-21 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
SG193216A1
(en)
|
2008-08-18 |
2013-09-30 |
Amgen Fremont Inc |
Antibodies to ccr2
|
|
KR101012267B1
(ko)
*
|
2008-08-29 |
2011-02-08 |
주식회사 세이프로드 |
파손이 방지되는 차선규제봉 및 차선규제봉 시공방법
|
|
US8475790B2
(en)
|
2008-10-06 |
2013-07-02 |
Bristol-Myers Squibb Company |
Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
|
|
ES2568509T3
(es)
|
2009-01-15 |
2016-04-29 |
Adaptive Biotechnologies Corporation |
Perfilado de la inmunidad adaptativa y métodos para la generación de anticuerpos monoclonales
|
|
AR075798A1
(es)
|
2009-03-05 |
2011-04-27 |
Abbott Lab |
Proteinas de union a il-17 (interleuquina 17)
|
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
|
CN102822200A
(zh)
|
2009-07-20 |
2012-12-12 |
百时美施贵宝公司 |
对增殖性疾病进行协同性治疗的抗ctla-4抗体与各种治疗方案的组合
|
|
MX2012002605A
(es)
|
2009-08-29 |
2012-04-02 |
Abbott Lab |
Proteinas terapeutico de union a dll4.
|
|
WO2011028811A2
(en)
|
2009-09-01 |
2011-03-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
|
US8435516B2
(en)
|
2009-10-12 |
2013-05-07 |
Pfizer Inc. |
Cancer treatment
|
|
US8716450B2
(en)
|
2009-10-15 |
2014-05-06 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
TW201121568A
(en)
|
2009-10-31 |
2011-07-01 |
Abbott Lab |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
|
US9175075B2
(en)
|
2009-12-08 |
2015-11-03 |
AbbVie Deutschland GmbH & Co. KG |
Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
|
|
KR20180044441A
(ko)
|
2010-03-02 |
2018-05-02 |
애브비 인코포레이티드 |
치료학적 ｄｌｌ４ 결합 단백질
|
|
CA2796339C
(en)
|
2010-04-15 |
2020-03-31 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
|
MX350723B
(es)
|
2010-05-14 |
2017-09-14 |
Abbvie Inc |
Proteínas de unión a il-1.
|
|
WO2011146382A1
(en)
|
2010-05-17 |
2011-11-24 |
Bristol-Myers Squibb Company |
Improved immunotherapeutic dosing regimens and combinations thereof
|
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
|
JP2013537415A
(ja)
|
2010-08-03 |
2013-10-03 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
|
EP2603524A1
(en)
|
2010-08-14 |
2013-06-19 |
AbbVie Inc. |
Amyloid-beta binding proteins
|
|
RS63063B1
(sr)
|
2010-08-19 |
2022-04-29 |
Zoetis Belgium S A |
Anti-ngf antitela i njihova upotreba
|
|
KR20130139884A
(ko)
|
2010-08-26 |
2013-12-23 |
애브비 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
WO2012072806A1
(en)
*
|
2010-12-02 |
2012-06-07 |
Pieris Ag |
Muteins of human lipocalin 2 with affinity for ctla-4
|
|
RS56737B1
(sr)
|
2010-12-14 |
2018-03-30 |
Nat Univ Singapore |
Humana monoklonska antitela koja su specifična za protein e virusa denge serotipa 1 i njihove upotrebe
|
|
WO2012121775A2
(en)
|
2010-12-21 |
2012-09-13 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
|
TW201307388A
(zh)
|
2010-12-21 |
2013-02-16 |
Abbott Lab |
Ｉｌ－１結合蛋白
|
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
|
WO2012142164A1
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
|
|
WO2013002362A1
(ja)
|
2011-06-30 |
2013-01-03 |
中外製薬株式会社 |
ヘテロ二量化ポリペプチド
|
|
AU2012283039A1
(en)
|
2011-07-13 |
2014-01-30 |
Abbvie Inc. |
Methods and compositions for treating asthma using anti-IL-13 antibodies
|
|
WO2013013029A1
(en)
|
2011-07-19 |
2013-01-24 |
The Board Of Trustees Of The University Of Illinois |
Anti-clta4, anti-glut2 protein for the treatment of type 1 diabetes
|
|
EP2750768B1
(en)
|
2011-08-30 |
2018-10-03 |
Astex Pharmaceuticals, Inc. |
Decitabine derivative formulations
|
|
CA2853357A1
(en)
|
2011-10-24 |
2013-05-02 |
Abbvie Inc. |
Immunobinders directed against tnf
|
|
TW201323440A
(zh)
|
2011-10-24 |
2013-06-16 |
Abbvie Inc |
抗骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）之免疫結合物
|
|
KR20140076602A
(ko)
|
2011-11-08 |
2014-06-20 |
화이자 인코포레이티드 |
항-m-csf 항체를 사용한 염증성 장애의 치료 방법
|
|
CA3204283A1
(en)
|
2011-12-14 |
2013-06-20 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
|
US9636398B2
(en)
|
2011-12-14 |
2017-05-02 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
|
TW201333035A
(zh)
|
2011-12-30 |
2013-08-16 |
Abbvie Inc |
針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
|
|
IL316441A
(en)
|
2012-01-27 |
2024-12-01 |
Abbvie Inc |
Composition and method for diagnosing and treating diseases associated with axonal degeneration of nerve cells
|
|
US20150110779A1
(en)
|
2012-03-15 |
2015-04-23 |
Bristol-Myers Squibb Company |
Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
|
|
US20150079100A1
(en)
|
2012-03-23 |
2015-03-19 |
Bristol-Myers Squibb Company |
Methods of treatments using ctla-4 antibodies
|
|
EP2836514A4
(en)
|
2012-04-13 |
2015-12-30 |
Childrens Medical Center |
TIKI INHIBITORS
|
|
PT2844282T
(pt)
|
2012-05-04 |
2019-07-23 |
Pfizer |
Antigénios associados à próstata e regimes de imunoterapêutica baseados em vacinas
|
|
WO2013169971A1
(en)
|
2012-05-10 |
2013-11-14 |
Bristol-Myers Squibb Company |
Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
|
|
SG11201407190TA
(en)
|
2012-05-15 |
2014-12-30 |
Bristol Myers Squibb Co |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
CA2875783C
(en)
|
2012-06-06 |
2018-12-11 |
Zoetis Llc |
Caninized anti-ngf antibodies and methods thereof
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
US9670276B2
(en)
|
2012-07-12 |
2017-06-06 |
Abbvie Inc. |
IL-1 binding proteins
|
|
US8968742B2
(en)
*
|
2012-08-23 |
2015-03-03 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
|
|
RU2017137740A
(ru)
|
2012-11-01 |
2019-02-11 |
Эббви Инк. |
Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения
|
|
US9550986B2
(en)
|
2012-12-21 |
2017-01-24 |
Abbvie Inc. |
High-throughput antibody humanization
|
|
CN105025884B
(zh)
|
2013-03-01 |
2019-08-20 |
阿斯泰克斯制药公司 |
药物组合
|
|
US9194873B2
(en)
|
2013-03-14 |
2015-11-24 |
Abbott Laboratories |
HCV antigen-antibody combination assay and methods and compositions for use therein
|
|
US9790478B2
(en)
|
2013-03-14 |
2017-10-17 |
Abbott Laboratories |
HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
|
|
RU2015142815A
(ru)
|
2013-03-14 |
2017-04-12 |
Паркаш ГИЛЛ |
Лечение рака с использованием антител, связывающихся с поверхностным grp78
|
|
EP3916103A1
(en)
|
2013-03-14 |
2021-12-01 |
Abbott Laboratories |
Hcv core lipid binding domain monoclonal antibodies
|
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
|
EP2970459A2
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Dual specific binding proteins directed against il-1beta and il-17
|
|
JP6581572B2
(ja)
|
2013-06-07 |
2019-09-25 |
デューク ユニバーシティ |
補体因子ｈ阻害薬
|
|
EP3659622A1
(en)
|
2013-08-08 |
2020-06-03 |
Cytune Pharma |
Combined pharmaceutical composition
|
|
EP3030575B1
(en)
|
2013-08-08 |
2018-07-11 |
Cytune Pharma |
Il-15 and il-15r-alpha sushi domain based modulokines
|
|
AU2014323523B2
(en)
|
2013-09-20 |
2020-02-20 |
Bristol-Myers Squibb Company |
Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
|
|
JP2016535989A
(ja)
|
2013-11-01 |
2016-11-24 |
ファイザー・インク |
前立腺関連抗原を発現させるためのベクター
|
|
WO2015069770A1
(en)
|
2013-11-05 |
2015-05-14 |
Cognate Bioservices, Inc. |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
|
EP3066127A1
(en)
|
2013-11-06 |
2016-09-14 |
Bristol-Myers Squibb Company |
Immunotherapeutic dosing regimens and combinations thereof
|
|
CA2936611A1
(en)
|
2014-01-13 |
2015-07-16 |
Pieris Pharmaceuticals Gmbh |
Multi-specific polypeptide useful for localized tumor immunomodulation
|
|
ES2860751T3
(es)
|
2014-05-28 |
2021-10-05 |
Agenus Inc |
Anticuerpos anti-GITR y procedimientos de uso de estos
|
|
SG11201610074YA
(en)
|
2014-06-06 |
2016-12-29 |
Bristol Myers Squibb Co |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
|
CN105296433B
(zh)
*
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
PT3186281T
(pt)
|
2014-08-28 |
2019-07-10 |
Halozyme Inc |
Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica
|
|
CA2944085C
(en)
|
2014-09-16 |
2018-04-10 |
Ease Charm Limited |
Anti-egfr antibody and uses of same
|
|
EP4029508A1
(en)
|
2014-10-10 |
2022-07-20 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using tlr9 agonists and checkpoint inhibitors
|
|
EA201700181A1
(ru)
|
2014-10-14 |
2017-09-29 |
Галозим, Инк. |
Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
|
|
CN107074976B
(zh)
*
|
2014-11-04 |
2020-10-09 |
北京韩美药品有限公司 |
同时阻断b7/cd28和il6/il6r/gp130信号通路的重组融合蛋白
|
|
WO2016074580A1
(zh)
*
|
2014-11-14 |
2016-05-19 |
中国科学院上海生命科学研究院 |
一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用
|
|
EP3221346B1
(en)
|
2014-11-21 |
2020-09-02 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
|
TWI711630B
(zh)
|
2014-11-21 |
2020-12-01 |
美商必治妥美雅史谷比公司 |
抗ｃｄ７３抗體及其用途
|
|
SG11201704343SA
(en)
|
2014-12-04 |
2017-06-29 |
Bristol Myers Squibb Co |
Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
|
|
CN104387453A
(zh)
*
|
2014-12-08 |
2015-03-04 |
深圳市同康生物医药有限公司 |
树突状细胞靶向肽及编码基因及应用
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
TN2017000267A1
(en)
|
2014-12-23 |
2018-10-19 |
Bristol Myers Squibb Co |
Antibodies to tigit
|
|
HUE053145T2
(hu)
|
2014-12-31 |
2021-06-28 |
Checkmate Pharmaceuticals Inc |
Kombinált tumor immunterápia
|
|
WO2016127052A1
(en)
|
2015-02-05 |
2016-08-11 |
Bristol-Myers Squibb Company |
Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
|
|
AU2016219170B2
(en)
*
|
2015-02-13 |
2021-09-09 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind CTLA4
|
|
US20180133327A1
(en)
|
2015-03-16 |
2018-05-17 |
Amal Therapeutics Sa |
Cell Penetrating Peptides and Complexes Comprising the Same
|
|
WO2016154629A1
(en)
|
2015-03-26 |
2016-09-29 |
Woman & Infants' Hospital Of Rhode Island |
Therapy for malignant disease
|
|
WO2016163489A1
(ja)
|
2015-04-07 |
2016-10-13 |
日本電気株式会社 |
医薬
|
|
CA2984975A1
(en)
|
2015-05-06 |
2016-11-10 |
Snipr Technologies Limited |
Altering microbial populations & modifying microbiota
|
|
JP7028765B2
(ja)
|
2015-05-22 |
2022-03-02 |
トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー |
ベンズアミドおよび活性化合物組成物および使用方法
|
|
TN2017000488A1
(en)
|
2015-05-29 |
2019-04-12 |
Bristol Myers Squibb Co |
Antibodies against ox40 and uses thereof
|
|
MX392748B
(es)
|
2015-05-29 |
2025-03-24 |
Abbvie Inc |
Anticuerpos anti-cd40 y sus usos.
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
EA201890162A1
(ru)
|
2015-06-29 |
2018-07-31 |
Бристол-Маерс Сквибб Компани |
Антитела к cd40 с повышенной агонистической активностью
|
|
EP3313528B1
(en)
|
2015-06-29 |
2021-08-04 |
Bristol-Myers Squibb Company |
Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer
|
|
WO2017004538A1
(en)
|
2015-07-02 |
2017-01-05 |
Otsuka Pharmaceutical Co., Ltd. |
Lyophilized pharmaceutical compositions
|
|
CN107921087A
(zh)
|
2015-07-16 |
2018-04-17 |
百欧肯治疗有限公司 |
治疗癌症的组合物及方法
|
|
NZ739503A
(en)
|
2015-07-16 |
2023-06-30 |
Bioxcel Therapeutics Inc |
A novel approach for treatment of cancer using immunomodulation
|
|
EP3331917A1
(en)
|
2015-08-04 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
US20180230431A1
(en)
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
|
AU2016319133B2
(en)
|
2015-09-11 |
2023-06-08 |
Mark C. Glassy |
Enhanced delivery of drugs to the brain
|
|
LT3370733T
(lt)
|
2015-11-02 |
2021-10-25 |
Board Of Regents, The University Of Texas System |
Cd40 aktyvinimo ir imuninės kontrolės taškų blokados būdai
|
|
JP2019503985A
(ja)
|
2015-11-03 |
2019-02-14 |
グリコミメティクス， インコーポレイテッド |
モノクローナル抗体、造血幹細胞の産生のための方法および組成物、ならびにそれらを使用する方法
|
|
JP2018532810A
(ja)
|
2015-11-07 |
2018-11-08 |
マルチビア インコーポレイテッド |
がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物
|
|
BR112018010172A2
(pt)
|
2015-11-19 |
2018-11-21 |
Bristol Myers Squibb Co |
anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
|
|
SG10201912984WA
(en)
|
2015-12-02 |
2020-03-30 |
Agenus Inc |
Antibodies and methods of use thereof
|
|
CA3006462C
(en)
|
2015-12-14 |
2023-10-31 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
|
|
US20190241658A1
(en)
|
2016-01-10 |
2019-08-08 |
Modernatx, Inc. |
Therapeutic mRNAs encoding anti CTLA-4 antibodies
|
|
KR20230038311A
(ko)
|
2016-03-04 |
2023-03-17 |
브리스톨-마이어스 스큅 컴퍼니 |
항-cd73 항체와의 조합 요법
|
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
|
JP7137474B2
(ja)
|
2016-03-15 |
2022-09-14 |
メルサナ セラピューティクス，インコーポレイティド |
ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法
|
|
RU2769314C1
(ru)
|
2016-03-16 |
2022-03-30 |
Амаль Терапьютикс Са |
Комбинация модулятора иммунных контрольных точек и комплекса, содержащего проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr, для применения в медицине
|
|
US11046782B2
(en)
|
2016-03-30 |
2021-06-29 |
Musc Foundation For Research Development |
Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
|
|
EP3436066A1
(en)
|
2016-04-01 |
2019-02-06 |
Checkmate Pharmaceuticals, Inc. |
Fc receptor-mediated drug delivery
|
|
SG10201913248VA
(en)
|
2016-04-18 |
2020-02-27 |
Celldex Therapeutics Inc |
Agonistic antibodies that bind human cd40 and uses thereof
|
|
CA3022377A1
(en)
|
2016-04-29 |
2017-11-02 |
Board Of Regents, The University Of Texas System |
Targeted measure of transcriptional activity related to hormone receptors
|
|
WO2017192874A1
(en)
|
2016-05-04 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Albumin-binding immunomodulatory compositions and methods of use thereof
|
|
WO2017201352A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
CN109641044A
(zh)
|
2016-05-30 |
2019-04-16 |
吉奥瓦科斯公司 |
用于产生对乙型肝炎病毒的免疫应答的组合物和方法
|
|
US10994033B2
(en)
|
2016-06-01 |
2021-05-04 |
Bristol-Myers Squibb Company |
Imaging methods using 18F-radiolabeled biologics
|
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
|
TWI784957B
(zh)
|
2016-06-20 |
2022-12-01 |
英商克馬伯有限公司 |
免疫細胞介素
|
|
RU2758007C2
(ru)
|
2016-06-30 |
2021-10-25 |
Онкорус, Инк. |
Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
|
|
CN109757103B
(zh)
|
2016-07-14 |
2024-01-02 |
百时美施贵宝公司 |
针对tim3的抗体及其用途
|
|
NL2017270B1
(en)
*
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
|
WO2018025221A1
(en)
|
2016-08-04 |
2018-02-08 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-icos and anti-pd-1 antibody combination therapy
|
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
|
JP7346291B2
(ja)
|
2016-09-21 |
2023-09-19 |
アマル セラピューティクス エスエー |
癌を治療するための細胞透過性ペプチド、マルチエピトープ、及びｔｌｒペプチドアゴニストを含む融合体
|
|
CN110267651B
(zh)
|
2016-09-27 |
2023-09-01 |
得克萨斯系统大学评议会 |
通过调节微生物组来增强免疫检查点阻断疗法的方法
|
|
US20180106800A1
(en)
|
2016-10-03 |
2018-04-19 |
Abbott Laboratories |
Methods of assessing uch-l1 status in patient samples
|
|
CN110035773B
(zh)
*
|
2016-10-10 |
2023-06-02 |
中美冠科生物技术（太仓）有限公司 |
新型抗ctla4抗体
|
|
EP3527216B1
(en)
|
2016-10-11 |
2024-02-14 |
NEC Corporation |
A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide
|
|
BR112019007365A2
(pt)
|
2016-10-12 |
2019-07-09 |
Univ Texas |
métodos e composições para imunoterapia com tusc2
|
|
JP7258747B2
(ja)
|
2016-10-28 |
2023-04-17 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗ｐｄ－１抗体を用いた尿路上皮癌の処置方法
|
|
CN118480125A
(zh)
*
|
2016-11-08 |
2024-08-13 |
齐鲁皮吉特湾生物治疗有限公司 |
抗pd1和抗ctla4抗体
|
|
US11883430B2
(en)
|
2016-11-09 |
2024-01-30 |
Musc Foundation For Research Development |
CD38-NAD+ regulated metabolic axis in anti-tumor immunotherapy
|
|
WO2018089628A1
(en)
|
2016-11-09 |
2018-05-17 |
Agenus Inc. |
Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
|
|
BR112019010020A2
(pt)
|
2016-11-17 |
2019-08-20 |
Univ Texas |
compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
|
|
JP7080234B2
(ja)
|
2016-11-23 |
2022-06-03 |
トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー |
ベンズアミドおよび活性化合物組成物および使用方法
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
WO2018099539A1
(en)
|
2016-11-29 |
2018-06-07 |
Horst Lindhofer |
Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
|
|
KR20190090823A
(ko)
|
2016-12-01 |
2019-08-02 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
조합 요법
|
|
US20190343803A1
(en)
|
2016-12-01 |
2019-11-14 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
CA3046961A1
(en)
|
2016-12-12 |
2018-06-21 |
Multivir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
|
WO2018110515A1
(ja)
|
2016-12-12 |
2018-06-21 |
第一三共株式会社 |
抗体－薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
|
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
|
JP7165995B2
(ja)
*
|
2017-02-21 |
2022-11-07 |
アールイーエムディー バイオセラピューティクス，インコーポレイテッド |
細胞傷害性ｔリンパ球抗原－４（ｃｔｌａ－４）に結合する抗体を使用した癌治療
|
|
JP7162398B2
(ja)
|
2017-02-24 |
2022-10-28 |
ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム |
早期膵がん検出アッセイ
|
|
US20180271996A1
(en)
|
2017-02-28 |
2018-09-27 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
|
EP3366703B1
(en)
|
2017-02-28 |
2019-04-03 |
Ralf Kleef |
Immune checkpoint therapy with hyperthermia
|
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
|
WO2018167778A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of diagnosing and prognosing cancer
|
|
US11016092B2
(en)
|
2017-03-23 |
2021-05-25 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1
|
|
KR20250036268A
(ko)
|
2017-03-31 |
2025-03-13 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
AU2018250688B2
(en)
|
2017-04-15 |
2024-07-04 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
|
|
US11760777B2
(en)
|
2017-04-26 |
2023-09-19 |
Bristol-Myers Squibb Company |
Methods of antibody production that minimize disulfide bond reduction
|
|
JP7080899B2
(ja)
|
2017-04-28 |
2022-06-06 |
アボット・ラボラトリーズ |
同じヒト対象に由来する少なくとも２つの試料に対して早期バイオマーカーを使用する、外傷性脳損傷の超急性の診断及び決定の一助となるための方法
|
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
|
KR20230053001A
(ko)
|
2017-05-19 |
2023-04-20 |
우시 바이올로직스 (상하이) 컴퍼니 리미티드 |
세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
|
|
CN108948194B
(zh)
*
|
2017-05-19 |
2023-02-17 |
上海药明生物技术有限公司 |
一种新的ctla-4单克隆抗体
|
|
AU2018272054B2
(en)
|
2017-05-25 |
2024-10-31 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
|
CN110719915A
(zh)
|
2017-05-25 |
2020-01-21 |
百时美施贵宝公司 |
包含经修饰的重链恒定区的抗体
|
|
WO2018222718A1
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Treatment of lag-3 positive tumors
|
|
JP7269183B2
(ja)
|
2017-05-30 |
2023-05-08 |
アボット・ラボラトリーズ |
心臓トロポニンｉを使用する、ヒト対象における軽度外傷性脳損傷を診断及び査定する一助となるための方法
|
|
CN110691795A
(zh)
|
2017-05-30 |
2020-01-14 |
百时美施贵宝公司 |
包含抗-lag3抗体、pd-1途径抑制剂和免疫治疗剂组合的组合物
|
|
CA3065304A1
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
|
|
EP4461825A3
(en)
|
2017-06-09 |
2024-11-20 |
Providence Health & Services - Oregon |
Tumor-infiltrating t-cells for use in the treatment of cancer
|
|
WO2019010131A1
(en)
|
2017-07-03 |
2019-01-10 |
Abbott Laboratories |
IMPROVED METHODS FOR MEASURING CARBOXY TERMINATION HYDROLASE LEVELS OF UBIQUITIN L1 IN BLOOD
|
|
EP3652211A1
(en)
|
2017-07-14 |
2020-05-20 |
Pfizer Inc. |
Antibodies to madcam
|
|
JP7159282B2
(ja)
|
2017-07-14 |
2022-10-24 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
Ｎｌｒｐ３モジュレーター
|
|
TWI799432B
(zh)
*
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
|
SG11202000932XA
(en)
|
2017-08-03 |
2020-02-27 |
Otsuka Pharma Co Ltd |
Drug compound and purification methods thereof
|
|
WO2019036855A1
(en)
|
2017-08-21 |
2019-02-28 |
Adagene Inc. |
Anti-cd137 molecules and use thereof
|
|
US12195536B2
(en)
|
2017-10-06 |
2025-01-14 |
The Wistar Institute Of Anatomy And Biology |
DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer
|
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
|
CA3081336A1
(en)
|
2017-10-12 |
2019-04-18 |
Gregory LIZEE |
T cell receptors for immunotherapy
|
|
CN111247169A
(zh)
|
2017-10-15 |
2020-06-05 |
百时美施贵宝公司 |
治疗肿瘤的方法
|
|
KR20200074214A
(ko)
|
2017-11-01 |
2020-06-24 |
브리스톨-마이어스 스큅 컴퍼니 |
암을 치료하는데 사용하기 위한 면역자극 효능작용 항체
|
|
CA3079999A1
(en)
|
2017-11-07 |
2019-05-16 |
The Board Of Regents Of The University Of Texas System |
Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer
|
|
US11638760B2
(en)
|
2017-11-27 |
2023-05-02 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
CN108003238B
(zh)
*
|
2017-11-30 |
2021-02-02 |
常州费洛斯药业科技有限公司 |
一种能特异识别ctla-4的全人源单克隆抗体或抗体片段及其方法和用途
|
|
AU2018378971B9
(en)
|
2017-12-09 |
2025-04-17 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase l1 (UCH-L1)
|
|
WO2019112860A1
(en)
|
2017-12-09 |
2019-06-13 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
|
|
BR112020012364A2
(pt)
*
|
2017-12-20 |
2020-11-24 |
Harbour Biomed (Shanghai) Co., Ltd |
anticorpos de ligação a ctla-4 e usos dos mesmos
|
|
CN111757757A
(zh)
|
2017-12-21 |
2020-10-09 |
梅尔莎纳医疗公司 |
吡咯并苯并二氮呯抗体共轭物
|
|
EP3732198A1
(en)
|
2017-12-27 |
2020-11-04 |
Bristol-Myers Squibb Company |
Anti-cd40 antibodies and uses thereof
|
|
EP3731850A4
(en)
|
2017-12-29 |
2021-12-01 |
Oncorus, Inc. |
ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
|
|
CN120192415A
(zh)
|
2018-01-12 |
2025-06-24 |
百时美施贵宝公司 |
抗tim3抗体及其用途
|
|
CA3088542A1
(en)
|
2018-01-22 |
2019-07-25 |
Bristol-Myers Squibb Company |
Compositions and methods of treating cancer
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
EP3752194A4
(en)
|
2018-02-13 |
2022-03-16 |
Checkmate Pharmaceuticals, Inc. |
ANTI-TUMOR IMMUNOTHERAPY COMPOSITIONS AND METHODS
|
|
MX2020009526A
(es)
|
2018-03-12 |
2020-10-28 |
Zoetis Services Llc |
Anticuerpos anti-ngf y metodos de estos.
|
|
JP2021517589A
(ja)
|
2018-03-12 |
2021-07-26 |
アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） |
癌の治療のための化学免疫療法を増強するためのカロリー制限模倣物の使用
|
|
EP3768698B1
(en)
|
2018-03-19 |
2025-02-12 |
MultiVir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
|
|
WO2019179388A1
(en)
*
|
2018-03-19 |
2019-09-26 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Novel anti-ctla-4 antibody polypeptide
|
|
WO2019183040A1
(en)
|
2018-03-21 |
2019-09-26 |
Five Prime Therapeutics, Inc. |
ANTIBODIES BINDING TO VISTA AT ACIDIC pH
|
|
MX2020009861A
(es)
|
2018-03-23 |
2020-10-08 |
Bristol Myers Squibb Co |
Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
|
|
SG11202009504YA
(en)
|
2018-03-25 |
2020-10-29 |
Snipr Biome Aps |
Treating & preventing microbial infections
|
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
|
AU2019243738B2
(en)
|
2018-03-27 |
2024-05-30 |
Board Of Regents, The University Of Texas System |
Compounds with anti-tumor activity against cancer cells bearing HER2 exon 19 mutations
|
|
KR20200139724A
(ko)
|
2018-03-30 |
2020-12-14 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
IL319506A
(en)
|
2018-04-09 |
2025-05-01 |
Checkmate Pharmaceuticals Inc |
Packaging of oligonucleotides in virus-like particles
|
|
IL278090B2
(en)
|
2018-04-18 |
2024-07-01 |
Xencor Inc |
Il-15/il-15rα heterodimeric fc fusion proteins and uses thereof
|
|
EP3781599A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
PE20210160A1
(es)
|
2018-04-25 |
2021-01-26 |
Innate Tumor Immunity Inc |
Moduladores de nlrp3
|
|
US12331068B2
(en)
|
2018-05-31 |
2025-06-17 |
Peloton Therapeutics, Inc. |
Compositions and methods for inhibiting CD73
|
|
WO2019241358A2
(en)
|
2018-06-12 |
2019-12-19 |
The Regents Of The University Of California |
Single-chain bispecific chimeric antigen receptors for the treatment of cancer
|
|
CN119390840A
(zh)
|
2018-07-09 |
2025-02-07 |
戊瑞治疗有限公司 |
结合到ilt4的抗体
|
|
PE20210687A1
(es)
|
2018-07-11 |
2021-04-08 |
Bristol Myers Squibb Co |
Anticuerpos de union a vista a ph acido
|
|
CA3106143A1
(en)
|
2018-07-11 |
2020-01-16 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
CA3106114A1
(en)
|
2018-07-20 |
2020-01-23 |
Surface Oncology, Inc. |
Anti-cd112r compositions and methods
|
|
ES2974964T3
(es)
|
2018-08-16 |
2024-07-02 |
Innate Tumor Immunity Inc |
Moduladores de NLRP3 derivados de imidazo[4,5-c]quinolina
|
|
CN112888677A
(zh)
|
2018-08-16 |
2021-06-01 |
先天肿瘤免疫公司 |
被取代的4-氨基-1H-咪唑并[4,5-c]喹啉化合物及其改进的制备方法
|
|
KR102768379B1
(ko)
|
2018-08-16 |
2025-02-13 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
이미다조[4,5-c]퀴놀린 유래 NLRP3-조정제
|
|
EP3617230A1
(en)
|
2018-09-03 |
2020-03-04 |
BioInvent International AB |
Novel antibodies and nucleotide sequences, and uses thereof
|
|
WO2020048942A1
(en)
|
2018-09-04 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
|
|
US20220073638A1
(en)
|
2018-09-19 |
2022-03-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
|
CN112105634B
(zh)
|
2018-09-21 |
2024-03-12 |
信达生物制药(苏州)有限公司 |
新型白介素2及其用途
|
|
AU2019343251B2
(en)
|
2018-09-21 |
2022-06-09 |
Innovent Biologics (Suzhou) Co., Ltd. |
Novel interleukin 2 and use thereof
|
|
US20220040183A1
(en)
|
2018-10-01 |
2022-02-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of stress granule formation for targeting the regulation of immune responses
|
|
WO2020072821A2
(en)
|
2018-10-03 |
2020-04-09 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
|
TW202035445A
(zh)
|
2018-10-10 |
2020-10-01 |
美商帝洛斯療法股份有限公司 |
抗lap抗體變異體及其用途
|
|
KR20210091710A
(ko)
|
2018-10-12 |
2021-07-22 |
젠코어 인코포레이티드 |
PD-1 표적화 IL-15/IL-15Rα Fc 융합 단백질 및 병용요법에서의 이의 용도
|
|
WO2020086724A1
(en)
|
2018-10-23 |
2020-04-30 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
WO2020092385A1
(en)
|
2018-10-29 |
2020-05-07 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
|
CN113330310A
(zh)
|
2018-11-09 |
2021-08-31 |
皮埃里亚生物科学有限责任公司 |
用于测定肿瘤微环境组成的方法和组合物
|
|
BR112021009111A2
(pt)
|
2018-11-16 |
2021-08-24 |
Bristol-Myers Squibb Company |
Anticorpos anti-nkg2a e usos dos mesmos
|
|
EP3883955A1
(en)
|
2018-11-19 |
2021-09-29 |
Board of Regents, The University of Texas System |
A modular, polycistronic vector for car and tcr transduction
|
|
EP3887823B1
(en)
|
2018-11-28 |
2024-01-17 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and kit for assaying lytic potential of immune effector cells
|
|
AU2019386140A1
(en)
|
2018-11-28 |
2021-06-24 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
|
WO2020112781A1
(en)
|
2018-11-28 |
2020-06-04 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
|
MX2021006393A
(es)
|
2018-11-29 |
2021-10-13 |
Univ Texas |
Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
|
|
US20220018835A1
(en)
|
2018-12-07 |
2022-01-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
|
|
MX2021006831A
(es)
|
2018-12-11 |
2021-07-02 |
Theravance Biopharma R&D Ip Llc |
Inhibidores de alk5.
|
|
US20220047556A1
(en)
|
2018-12-17 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sulconazole as a furin inhibitor
|
|
EA202191784A1
(ru)
|
2018-12-26 |
2021-10-20 |
Сити Оф Хоуп |
Активируемые маскированные связывающие белки к ctla4
|
|
US20220056481A1
(en)
|
2018-12-28 |
2022-02-24 |
Transgene |
M2-defective poxvirus
|
|
CN113286786A
(zh)
|
2019-01-14 |
2021-08-20 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
|
KR102815870B1
(ko)
|
2019-01-14 |
2025-05-30 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
암의 치료에 사용하기 위한 헤테로시클릭 nlrp3 조정제
|
|
CN113286787A
(zh)
|
2019-01-14 |
2021-08-20 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
|
JP7373571B2
(ja)
|
2019-01-14 |
2023-11-02 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
がん治療に用いるためのｎｌｒｐ３モジュレーターとしての置換キナゾリン
|
|
IL284868B2
(en)
|
2019-01-15 |
2025-09-01 |
Inst Nat Sante Rech Med |
Mutant interleukin-34 (IL-34) polypeptides and their use for medical therapy
|
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
|
JP7650507B2
(ja)
|
2019-03-13 |
2025-03-25 |
イーザアールエヌーエー イムノセラピーズ エンヴェー |
ｍＲＮＡワクチン
|
|
US20220195046A1
(en)
|
2019-03-28 |
2022-06-23 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
WO2020198672A1
(en)
|
2019-03-28 |
2020-10-01 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
US20200318200A1
(en)
|
2019-04-02 |
2020-10-08 |
The Brigham And Women's Hospital, Inc. |
Methods for Identifying Progression of a Primary Melanoma
|
|
WO2020201362A2
(en)
|
2019-04-02 |
2020-10-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
|
EP3952850A1
(en)
|
2019-04-09 |
2022-02-16 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
|
|
WO2020212484A1
(en)
|
2019-04-17 |
2020-10-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
|
|
CN114144514A
(zh)
|
2019-05-09 |
2022-03-04 |
富士胶片细胞动力公司 |
产生肝细胞的方法
|
|
EP3968971A1
(en)
|
2019-05-17 |
2022-03-23 |
Cancer Prevention Pharmaceuticals, Inc. |
Methods for treating familial adenomatous polyposis
|
|
KR20220016157A
(ko)
|
2019-05-30 |
2022-02-08 |
브리스톨-마이어스 스큅 컴퍼니 |
세포 국재화 시그너쳐 및 조합 요법
|
|
CN114174538A
(zh)
|
2019-05-30 |
2022-03-11 |
百时美施贵宝公司 |
适合于免疫肿瘤学疗法的多肿瘤基因特征
|
|
WO2020243568A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
|
|
CA3144535A1
(en)
|
2019-06-03 |
2020-12-10 |
The University Of Chicago |
Methods and compositions for treating cancer with collagen binding drug carriers
|
|
WO2020247973A1
(en)
|
2019-06-03 |
2020-12-10 |
The University Of Chicago |
Methods and compositions for treating cancer with cancer-targeted adjuvants
|
|
US20210038684A1
(en)
|
2019-06-11 |
2021-02-11 |
Alkermes Pharma Ireland Limited |
Compositions and Methods for Cancer Immunotherapy
|
|
US20220387573A1
(en)
|
2019-06-27 |
2022-12-08 |
Etherna Immunotherapies Nv |
Combination therapy
|
|
CA3138188A1
(en)
|
2019-07-02 |
2021-01-07 |
Fred Hutchinson Cancer Research Center |
Recombinant ad35 vectors and related gene therapy improvements
|
|
CN119241706A
(zh)
|
2019-07-15 |
2025-01-03 |
英特维特国际股份有限公司 |
针对犬ctla-4的犬源化抗体
|
|
CA3145347A1
(en)
|
2019-07-15 |
2021-01-21 |
Intervet International B.V. |
Caninized antibodies to human and canine ctla-4
|
|
JPWO2021024742A1
(OSRAM)
*
|
2019-08-06 |
2021-02-11 |
|
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
US20220402901A1
(en)
|
2019-09-17 |
2022-12-22 |
Bial - R&D Investments, S.A. |
Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
|
|
AU2020349516A1
(en)
|
2019-09-17 |
2022-03-17 |
Bial-R&D Investments, S.A. |
Substituted imidazole carboxamides and their use in the treatment of medical disorders
|
|
CN114901652A
(zh)
|
2019-09-17 |
2022-08-12 |
比亚尔R&D投资股份公司 |
用于治疗医学病症的经取代的饱和和不饱和n-杂环甲酰胺及相关化合物
|
|
TW202124448A
(zh)
|
2019-09-19 |
2021-07-01 |
美商必治妥美雅史谷比公司 |
於酸性pH結合VISTA之抗體
|
|
EP4031873A1
(en)
|
2019-09-22 |
2022-07-27 |
Bristol-Myers Squibb Company |
Quantitative spatial profiling for lag-3 antagonist therapy
|
|
EP4034253A4
(en)
|
2019-09-23 |
2024-02-07 |
The Regents Of The University Of Michigan |
COMPOSITIONS AND METHODS FOR INCREASING THE EFFECTIVENESS OF IMMUNOTHERAPIES AND VACCINES
|
|
AU2020353672A1
(en)
|
2019-09-25 |
2022-03-31 |
Surface Oncology, LLC |
Anti-IL-27 antibodies and uses thereof
|
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
|
EP4037700A2
(en)
|
2019-10-03 |
2022-08-10 |
Xencor, Inc. |
Targeted il-12 heterodimeric fc-fusion proteins
|
|
EP4037710A1
(en)
|
2019-10-04 |
2022-08-10 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
BR112022007632A2
(pt)
|
2019-10-25 |
2022-07-12 |
Daiichi Sankyo Co Ltd |
Composição farmacêutica e preparação de kit para tratamento de câncer, e, métodos para tratamento de câncer e de um paciente com câncer
|
|
US20220380765A1
(en)
|
2019-11-02 |
2022-12-01 |
Board Of Regents, The University Of Texas System |
Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
|
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
BR112022008191A2
(pt)
|
2019-11-08 |
2022-07-12 |
Bristol Myers Squibb Co |
Terapia com antagonista de lag-3 para melanoma
|
|
JP2023502662A
(ja)
|
2019-11-22 |
2023-01-25 |
セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー |
Ａｌｋ５阻害剤としての置換１，５－ナフチリジンまたはキノリン
|
|
JPWO2021106978A1
(OSRAM)
|
2019-11-27 |
2021-06-03 |
|
|
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
|
JP2023510108A
(ja)
|
2019-12-19 |
2023-03-13 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ
|
|
KR102645629B1
(ko)
|
2019-12-27 |
2024-03-07 |
추가이 세이야쿠 가부시키가이샤 |
항ctla-4 항체 및 그의 사용
|
|
EP4087922A4
(en)
|
2020-01-07 |
2024-01-10 |
Board of Regents, The University of Texas System |
Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
|
|
KR20220127848A
(ko)
|
2020-01-10 |
2022-09-20 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
Nlrp3 조정제
|
|
US20230061973A1
(en)
|
2020-02-05 |
2023-03-02 |
Larimar Therapeutics, Inc. |
Tat peptide binding proteins and uses thereof
|
|
EP4100426A1
(en)
|
2020-02-06 |
2022-12-14 |
Bristol-Myers Squibb Company |
Il-10 and uses thereof
|
|
WO2021167908A1
(en)
|
2020-02-17 |
2021-08-26 |
Board Of Regents, The University Of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
|
US20230045494A1
(en)
|
2020-02-28 |
2023-02-09 |
Orega Biotech |
Combination therapies based on ctla4 and il-17b inhibitors
|
|
KR20220150353A
(ko)
|
2020-03-05 |
2022-11-10 |
네오티엑스 테라퓨틱스 엘티디. |
면역 세포를 사용하여 암을 치료하기 위한 방법 및 조성물
|
|
WO2021183428A1
(en)
|
2020-03-09 |
2021-09-16 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
|
JP2023519346A
(ja)
|
2020-03-27 |
2023-05-10 |
メンドゥス・ベスローテン・フェンノートシャップ |
養子細胞療法の有効性を増強するための白血病由来の改変細胞のエクスビボ（ｅｘ ｖｉｖｏ）使用
|
|
TW202204339A
(zh)
|
2020-03-31 |
2022-02-01 |
美商施萬生物製藥研發 Ip有限責任公司 |
經取代的嘧啶及使用方法
|
|
EP4132971A1
(en)
|
2020-04-09 |
2023-02-15 |
Merck Sharp & Dohme LLC |
Affinity matured anti-lap antibodies and uses thereof
|
|
CA3175523A1
(en)
|
2020-04-13 |
2021-10-21 |
Antti Virtanen |
Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
|
|
WO2021216670A1
(en)
|
2020-04-21 |
2021-10-28 |
University Of Rochester |
Inhibitors of human epididymus protein 4
|
|
MX2022013065A
(es)
|
2020-04-22 |
2022-12-08 |
Iovance Biotherapeutics Inc |
Sistemas y metodos para coordinar la manufactura de celulas para inmunoterapia especifica de acuerdo al paciente.
|
|
WO2021228178A1
(en)
|
2020-05-13 |
2021-11-18 |
Adagene Ag |
Compositions and methods for treating cancer
|
|
IL297437A
(en)
|
2020-05-13 |
2022-12-01 |
Disc Medicine Inc |
Anti-hemoglobin (hjv) antibodies for the treatment of myelofibrosis
|
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
AU2021275239A1
(en)
|
2020-05-21 |
2022-12-15 |
Board Of Regents, The University Of Texas System |
T cell receptors with VGLL1 specificity and uses thereof
|
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
|
EP4162037A1
(en)
|
2020-06-03 |
2023-04-12 |
MV Biotherapeutics SA |
Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof
|
|
EP4161653A1
(en)
|
2020-06-03 |
2023-04-12 |
Bionecure Therapeutics, Inc. |
Trophoblast cell-surface antigen-2 (trop-2) antibodies
|
|
EP4165041A1
(en)
|
2020-06-10 |
2023-04-19 |
Theravance Biopharma R&D IP, LLC |
Naphthyridine derivatives useful as alk5 inhibitors
|
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
AU2021302958A1
(en)
|
2020-06-30 |
2023-02-16 |
Mendus B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
|
WO2022003156A1
(en)
|
2020-07-02 |
2022-01-06 |
Oncurious Nv |
Ccr8 non-blocking binders
|
|
CA3182579A1
(en)
|
2020-07-07 |
2022-01-13 |
Ugur Sahin |
Therapeutic rna for hpv-positive cancer
|
|
WO2022010847A1
(en)
|
2020-07-07 |
2022-01-13 |
Cancure, Llc |
Mic antibodies and binding agents and methods of using the same
|
|
JP2023534987A
(ja)
|
2020-07-24 |
2023-08-15 |
アムジエン・インコーポレーテツド |
Ｓａｒｓ－ｃｏｖ２スパイクタンパク質に由来する免疫原
|
|
US20230295146A1
(en)
|
2020-07-24 |
2023-09-21 |
The University Of Rochester |
Inhibitors of interleukin-1 receptor-associated kinases 1 and 4
|
|
KR20230042301A
(ko)
|
2020-08-04 |
2023-03-28 |
애벗트 라보라토리이즈 |
샘플에서 sars-cov-2 단백질을 검출하기 위한 개선된 방법 및 키트
|
|
CN112359052B
(zh)
*
|
2020-08-20 |
2023-01-03 |
山东兴瑞生物科技有限公司 |
抗EpCAM嵌合抗原受体的编码基因、制备方法、具有该基因的质粒、免疫细胞及其应用
|
|
JP2023540255A
(ja)
|
2020-08-28 |
2023-09-22 |
ブリストル－マイヤーズ スクイブ カンパニー |
肝細胞癌のためのｌａｇ－３アンタゴニスト療法
|
|
US20230303700A1
(en)
|
2020-08-31 |
2023-09-28 |
Bristol-Myers Squibb Company |
Cell localization signature and immunotherapy
|
|
MX2023004493A
(es)
|
2020-10-23 |
2023-05-10 |
Bristol Myers Squibb Co |
Terapia de agonista del gen-3 de activacion del linfocito (lag-3) para cancer de pulmon.
|
|
CA3200661A1
(en)
|
2020-11-05 |
2022-05-12 |
Board Of Regents, The University Of Texas System |
Engineered t cell receptors targeting egfr antigens and methods of use
|
|
AU2021377699A1
(en)
|
2020-11-13 |
2023-06-15 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
|
US20220162288A1
(en)
|
2020-11-25 |
2022-05-26 |
Catamaran Bio, Inc. |
Cellular therapeutics engineered with signal modulators and methods of use thereof
|
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
|
WO2022119841A1
(en)
|
2020-12-01 |
2022-06-09 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
CN116601170A
(zh)
*
|
2020-12-10 |
2023-08-15 |
上海药明生物技术有限公司 |
抗p-钙粘蛋白抗体及其用途
|
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
CA3206304A1
(en)
|
2020-12-24 |
2022-06-30 |
Vib Vzw |
Human ccr8 binders
|
|
US20240052044A1
(en)
|
2020-12-24 |
2024-02-15 |
Vib Vzw |
Non-blocking human ccr8 binders
|
|
US20240052045A1
(en)
|
2020-12-24 |
2024-02-15 |
Vib Vzw |
Murine cross-reactive human ccr8 binders
|
|
SMT202500208T1
(it)
|
2020-12-28 |
2025-07-22 |
Bristol Myers Squibb Co |
Composizioni anticorpali e metodi per il loro uso
|
|
CA3196999A1
(en)
|
2020-12-28 |
2022-07-07 |
Masano HUANG |
Methods of treating tumors
|
|
EP4271998A1
(en)
|
2020-12-30 |
2023-11-08 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
|
JP2024503480A
(ja)
|
2021-01-19 |
2024-01-25 |
ウィリアム マーシュ ライス ユニバーシティ |
ポリペプチドの骨特異的送達法
|
|
CA3203705A1
(en)
|
2021-01-22 |
2022-07-28 |
Erik Hans MANTING |
Methods of tumor vaccination
|
|
WO2022165214A1
(en)
|
2021-01-29 |
2022-08-04 |
Board Of Regents, The University Of Texas System |
Methods of treating cancer with kinase inhibitors
|
|
AU2022235341A1
(en)
|
2021-03-12 |
2023-09-21 |
Mendus B.V. |
Methods of vaccination and use of cd47 blockade
|
|
US20240376224A1
(en)
|
2021-04-02 |
2024-11-14 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
EP4319755A4
(en)
|
2021-04-08 |
2025-03-26 |
Board of Regents, The University of Texas System |
Compounds and methods for theranostic targeting of parp activity
|
|
EP4070799A1
(en)
|
2021-04-08 |
2022-10-12 |
Nuvamid SA |
Compositions for the improvement of sport performance
|
|
CN117279664A
(zh)
|
2021-04-10 |
2023-12-22 |
普方生物制药美国公司 |
Folr1结合剂、其偶联物及其使用方法
|
|
EP4326321A1
(en)
|
2021-04-20 |
2024-02-28 |
Institut Curie |
Compositions and methods for use in immunotherapy
|
|
EP4079311B1
(en)
|
2021-04-20 |
2025-10-01 |
Nuvamid SA |
Nmn and derivatives for use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
|
|
EP4079310A1
(en)
|
2021-04-20 |
2022-10-26 |
Nuvamid SA |
Nmn and derivatives for its use in the treatment of alpha-synucleinopathies
|
|
TW202308699A
(zh)
|
2021-04-23 |
2023-03-01 |
美商普方生物製藥美國公司 |
Ｃｄ７０結合劑、其結合物及其使用方法
|
|
BR112023024169A2
(pt)
|
2021-05-18 |
2024-02-06 |
Abbott Lab |
Métodos para avaliar lesão cerebral em um indivíduo pediátrico
|
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
|
BR112023022097A2
(pt)
|
2021-06-07 |
2023-12-19 |
Agonox Inc |
Cxcr5, pd-1 e icos expressando células t cd4 reativas de tumor e seu uso
|
|
WO2022266034A1
(en)
|
2021-06-14 |
2022-12-22 |
Abbott Laboratories |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
|
US20240002510A2
(en)
|
2021-06-25 |
2024-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ctla-4 antibody and use thereof
|
|
KR102690145B1
(ko)
|
2021-06-25 |
2024-07-30 |
추가이 세이야쿠 가부시키가이샤 |
항ctla-4 항체의 사용
|
|
IL309115A
(en)
|
2021-06-25 |
2024-02-01 |
Chugai Pharmaceutical Co Ltd |
Anti-CTLA-4 antibodies
|
|
WO2023280790A1
(en)
|
2021-07-05 |
2023-01-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
|
|
MX2024000674A
(es)
|
2021-07-13 |
2024-02-07 |
BioNTech SE |
Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
|
|
AU2022324040A1
(en)
|
2021-08-04 |
2024-02-22 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
|
MX2024002281A
(es)
|
2021-08-23 |
2024-05-20 |
Immunitas Therapeutics Inc |
Anticuerpos anti-cd161 y usos de los mismos.
|
|
AU2022339759A1
(en)
|
2021-08-31 |
2024-03-07 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
|
CN118715440A
(zh)
|
2021-08-31 |
2024-09-27 |
雅培实验室 |
诊断脑损伤的方法和系统
|
|
AU2022354059A1
(en)
|
2021-09-30 |
2024-03-28 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
|
JP2024537176A
(ja)
|
2021-10-05 |
2024-10-10 |
サイトヴィア セラピューティクス， エルエルシー |
ナチュラルキラー細胞及びその使用方法
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
TW202330612A
(zh)
|
2021-10-20 |
2023-08-01 |
日商武田藥品工業股份有限公司 |
靶向ｂｃｍａ之組合物及其使用方法
|
|
WO2023076880A1
(en)
|
2021-10-25 |
2023-05-04 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
|
MX2024005053A
(es)
|
2021-10-29 |
2024-05-10 |
Bristol Myers Squibb Co |
Terapia con antagonista del gen de activacion de linfocitos 3 (lag-3) para cancer hematologico.
|
|
JP2024540536A
(ja)
|
2021-11-19 |
2024-10-31 |
アーディアジェン コーポレーション |
Ｇｐｃ３結合剤、そのコンジュゲートおよびその使用方法
|
|
AU2022396272A1
(en)
*
|
2021-11-24 |
2024-06-06 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against ctla-4 and methods of use thereof
|
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
|
TW202332687A
(zh)
|
2021-12-23 |
2023-08-16 |
比利時商ｅＴｈｅＲＮＡ免疫治療公司 |
免疫刺激性mrna組成物及其用途
|
|
EP4469477A1
(en)
|
2022-01-26 |
2024-12-04 |
Bristol-Myers Squibb Company |
Combination therapy for hepatocellular carcinoma
|
|
JP2025507303A
(ja)
|
2022-02-04 |
2025-03-18 |
アボット・ラボラトリーズ |
試料におけるユビキチンカルボキシ末端ヒドロラーゼｌ１及び／又はグリア原線維性酸性タンパク質の存在を検出する又はその量を測定するためのラテラルフロー方法、アッセイ及びデバイス
|
|
CN118765284A
(zh)
|
2022-02-25 |
2024-10-11 |
百时美施贵宝公司 |
结直肠癌的组合疗法
|
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
CN119156403A
(zh)
|
2022-03-08 |
2024-12-17 |
阿伦蒂斯治疗股份公司 |
抗紧密连接蛋白-1抗体增加t细胞可用性的用途
|
|
MX2024011278A
(es)
|
2022-03-15 |
2024-09-25 |
Compugen Ltd |
Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer.
|
|
US20250195645A1
(en)
|
2022-03-16 |
2025-06-19 |
Daiichi Sankyo Company, Limited |
Combination of multispecific molecule and immune checkpoint inhibitor
|
|
WO2023178329A1
(en)
|
2022-03-18 |
2023-09-21 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
JP2025512401A
(ja)
|
2022-04-15 |
2025-04-17 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス
|
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
|
WO2023213763A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
|
JP2025518785A
(ja)
|
2022-06-02 |
2025-06-19 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗体組成物及びその使用方法
|
|
AR129560A1
(es)
|
2022-06-08 |
2024-09-04 |
Tidal Therapeutics Inc |
Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos
|
|
GB202209518D0
(en)
|
2022-06-29 |
2022-08-10 |
Snipr Biome Aps |
Treating & preventing E coli infections
|
|
AU2023298134A1
(en)
|
2022-06-29 |
2024-11-28 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
|
WO2024003353A1
(en)
|
2022-07-01 |
2024-01-04 |
Transgene |
Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
|
|
MA71616A
(fr)
|
2022-07-28 |
2025-05-30 |
Daiichi Sankyo Company, Limited |
Association d'un conjugué anticorps-médicament et d'un inhibiteur de point de contrôle bispécifique
|
|
WO2024028794A1
(en)
|
2022-08-02 |
2024-02-08 |
Temple Therapeutics BV |
Methods for treating endometrial and ovarian hyperproliferative disorders
|
|
WO2024052356A1
(en)
|
2022-09-06 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
|
|
CN120188044A
(zh)
|
2022-09-15 |
2025-06-20 |
雅培实验室 |
用于区分轻度创伤性脑损伤与超轻度创伤性脑损伤的生物标志物和方法
|
|
WO2024086827A2
(en)
|
2022-10-20 |
2024-04-25 |
Repertoire Immune Medicines, Inc. |
Cd8 t cell targeted il2
|
|
IL320733A
(en)
|
2022-11-21 |
2025-07-01 |
Iovance Biotherapeutics Inc |
Two-dimensional processes for expanding tumor-infiltrating lymphocytes and treatments thereof
|
|
AU2023393653A1
(en)
|
2022-12-14 |
2025-05-22 |
Astellas Pharma Europe Bv |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
|
|
WO2024137776A1
(en)
|
2022-12-21 |
2024-06-27 |
Bristol-Myers Squibb Company |
Combination therapy for lung cancer
|
|
WO2024163477A1
(en)
|
2023-01-31 |
2024-08-08 |
University Of Rochester |
Immune checkpoint blockade therapy for treating staphylococcus aureus infections
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
WO2024211475A1
(en)
|
2023-04-04 |
2024-10-10 |
Abbott Laboratories |
Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
|
|
WO2024213767A1
(en)
|
2023-04-14 |
2024-10-17 |
Institut National de la Santé et de la Recherche Médicale |
Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors
|
|
WO2024226969A1
(en)
|
2023-04-28 |
2024-10-31 |
Abbott Point Of Care Inc. |
Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
|
|
WO2024261302A1
(en)
|
2023-06-22 |
2024-12-26 |
Institut National de la Santé et de la Recherche Médicale |
Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
|
|
EP4484445A1
(en)
|
2023-06-26 |
2025-01-01 |
Universität zu Köln |
Hcmv neutralizing antibodies
|
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|
|
WO2025003193A1
(en)
|
2023-06-26 |
2025-01-02 |
Institut National de la Santé et de la Recherche Médicale |
Sertraline and indatraline for disrupting intracellular cholesterol trafficking and subsequently inducing lysosomal damage and anti-tumor immunity
|
|
WO2025012417A1
(en)
|
2023-07-13 |
2025-01-16 |
Institut National de la Santé et de la Recherche Médicale |
Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
WO2025050009A2
(en)
|
2023-09-01 |
2025-03-06 |
Children's Hospital Medical Center |
Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
|
|
WO2025061994A1
(en)
|
2023-09-21 |
2025-03-27 |
Domain Therapeutics |
Anti-ccr8 monoclonal antibodies and their therapeutic use
|
|
EP4590714A1
(en)
|
2023-09-21 |
2025-07-30 |
Domain Therapeutics |
Anti-ccr8 monoclonal antibodies and their therapeutic use
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025121445A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
EP4574165A1
(en)
|
2023-12-21 |
2025-06-25 |
Egle Therapeutics |
Immunocytokine for cancer treatment
|
|
WO2025133175A1
(en)
|
2023-12-21 |
2025-06-26 |
Egle Therapeutics |
Immunocytokine for cancer treatment
|
|
WO2025145207A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg-depleting agent
|
|
WO2025174825A2
(en)
|
2024-02-12 |
2025-08-21 |
Aera Therapeutics, Inc. |
Delivery compositions
|
|
US20250269052A1
(en)
|
2024-02-27 |
2025-08-28 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibody drug conjugates
|
|
WO2025184208A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|